Clinical follow-up information also demonstrated that the HCC patients who showed co-expression of OCT4 and BIRC5 in cancer tissues had poorer disease-free survival (DFS) and overall survival (OS) than patients who were negative for both OCT4 and BIRC5 (Additional file 4: Figure S2). The gene discussed is BIRC5; the disease is cancer.